Monthly Archives: January 2017

RepliCel Life Sciences, A Leader in the Multi-Billion Dollar Regenerative Medicine Industry

BEND, OR / ACCESSWIRE / January 30, 2017 / RepliCel Life Sciences (OTCQB: REPCF) (TSX-V: RP.V) (RepliCel or the Company) is a clinical-stage regenerative medicine company developing autologous [cells or tissues obtained from the same individual] cell therapies designed to address conditions caused by a deficit of healthy cells required for normal healing and function. The Company’s current clinical focus is on three areas: the repair of chronically injured tendons; restoring damaged skin; and the rejuvenation of hair growth.

Source: RepliCel

RepliCel’s product portfolio has the potential for large commercial applications, containing:

Two distinct cell therapy platforms built on hair follicle cell expertise

Unique dermal injector device

Strong IP protecting the process & use of hair follicle cells in a variety of indications

Pipeline

The Company currently has 4 products in its pipeline:

RCT-01 is for the treatment of chronic tendinosis caused by acute and chronic tensile overuse. RCT-01 is undergoing a Phase1/2 single-center trial investigating the use of the Company’s type 1 collagen-expressing, follicle-derived fibroblasts as a treatment for chronically injured ankle tendons. Initial clinical data from the RCT-01 clinical trial is anticipated during the first quarter of 2017.

Source: RepliCel

RCS-01 is for the treatment of patients suffering from aged and UV-damaged skin. RCS-01 is in a Phase 1 skin rejuvenation study for the Company’s type 1 collagen-expressing, follicle-derived fibroblasts as a treatment for UV-damaged and aged skin. While this trial is a Phase 1 trial, it has been designed to also produce significant biological data measuring whether or not, and to what extent, any aesthetically meaningful rebuilding of the dermal extracellular matrix under aging and sun-damaged skin is occurring. Quantitative data is anticipated to be generated from the histopathology and gene expression analysis of the tissue biopsied in the study. The data gathered from the study is expected to be significantly meaningful in the continued development of RCS-01. Initial clinical data from the RCS-01 clinical trial is anticipated during the first quarter of 2017.

Source: RepliCel

RCH-01 is an autologous cell therapy utilizing dermal sheath cup cells isolated for the hair follicle to treat androgenetic alopecia [Androgenetic alopecia is commonly referred to as male-pattern hair loss and female-pattern hair loss]. RCH-01 is now under investigation at Tokyo Medical University Hospital and Toho University Ohasi Medical Center, with the study funded by Shiseido Company, who RepliCel has a licensing and financing arrangement with. Additionally, a clinical date from a previously completed Phase 1 study of RCH-01 is anticipated to be released during the first quarter of 2017. This clinical study’s data will include 12 and 24-month efficacy data, along with 5-year safety data.

Source: RepliCel

RCI-02 is a dermal injector device, and the first of several devices the Company believes its dermal injection-related intellectual property will lead to. RCI-02 is designed for the injection of hyaluronic acid-based dermal fillers, although the device will be capable of being used for other products with similar injection profiles. The RCI-02 has several advantages over currently available devices, with what the Company describes as unparalleled control over injection depth, dose, and rate of deposition, along with a feature that numbs the skin, eliminating the need for local anesthetic injections. Additionally, the Company anticipates the adoption of its RCI-02 device will allow practitioners the ability to delegate more injection procedures to lower-skilled technicians, while ensuring a better patient experience and more consistent outcomes. In 2017, the Company is projected to complete manufacturing of functional and tested prototypes, which is anticipated to be sufficient to support their filing for a CE mark application with label approval for injection of hyaluronic acid-based dermal fillers. The CE mark is required to sell the device in Europe; RepliCel’s CEO recently stated he expects the Company to be posting revenue from the RCI-02 by 2018.

Source: RepliCel

RepliCel restructured many aspects of the Company during the first 3 quarters of 2016, and successfully completed a capital raise in October 2016. With adequate funding and several material milestones anticipated during the next three months, the Company’s management team is prepared for 2017, and what they believe will unquestionably be the Company’s most exciting year.

Summary

RepliCel (REPCF; RP.V) is a company on the verge of change. Each of the Company’s products is positioned to enter a total market in the billion of dollars. With significant milestones expected to be announced in all its product categories in the near future, we think your personal due-diligence will show RepliCel to be a compelling near-term investment opportunity.

Disclaimers & Disclosures:

For a full list of disclaimers and disclosures, please visit: http://sylvacap.com/disclaimer

Contact: info@sylvacap.com

SOURCE: Sylva International, LLC

ReleaseID: 453891

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Facebook, Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / January 30, 2017 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Facebook, Inc. (“Facebook” or the “Company”) (NASDAQ: FB). Investors, who purchased or otherwise acquired shares between April 1, 2015 and November 16, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the January 23, 2017 lead plaintiff motion deadline.

If you purchased shares of Facebook during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The Complaint alleges that Facebook introduced advertising and content “metrics” to help advertisers assess feedback for paid advertising purchases and to “better understand how people respond to (their) videos on Facebook,” by assessing the reach of Facebook advertisements and campaigns. Facebook marketed its new advertising assessment as an important tool to measure engagement with paid campaigns and advertisements. Facebook does not use a third-party tool to independently determine the accuracy of information and new metric tools.

On April 1, 2015, Facebook noted problems with the marketing and content metrics, but did not reveal this information to the public and did not reveal these errors in its SEC filings. The company still sold a significant amount of Facebook shares for profit, given this information. Facebook stated that it found problems in its video advertising metric, that it had falsified its average viewing time results, understated its significance, gave conflicting information about the error, and did not release other information about the problems. Facebook did not inform investors of the effect the errors would have on future ad revenue. After announcing an expected reduction in ad revenue and capital expenditures, the value of Facebook stock dropped, causing investors serious harm.

If you wish to learn more about this lawsuit at no charge to you, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contacts

Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 453886

Glycine value and volume market 2017 Market analytics by Type and Application forecasts to 2022

Glycine -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2022

Pune, India – January 30, 2017 /MarketersMedia/ —

Glycine Industry

Description

Wiseguyreports.Com Adds “Glycine -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database

This study gives an insight into global Glycine value and volume market. Market analytics by Type and Application are provided in this niche report. The market is divided by Type into L- Glycine & its Derivatives, D – Glycine Derivatives and other (Protected Glycines, DL Glycine Derivatives): Application into Pharmaceutical/Nutraceutical, Agrochemical, Food and Other. Predictions and estimations both in value (US$) and Volume (Metric Tons) for the analysis period 2010-2022 are also illustrated by geographic regions encompassing China, North America, Europe, Asia-Pacific, and Rest of World.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/905742-glycine-market-research-report

Highlights

Now a days amino acids are not only used as a supplement but also for other uses (to cure some diseases , as a feed additive, etc). Amino acids are produced through 3 processes – Fermentative, Enzymatic and Chemical. There has been a substantial increase in the demand for amino acids in the last thirty years.

There is a steady 5-10% growth rate in the market. Glycine is the smallest of all the amino acids. While almost all amino acids can be produced in two forms – the L and D form, it is not so in the case of glycine. Glycine is widely used in Pharmaceuticals.

Key Players

Chiyuen International Trading Limited (China)

Hebei Donghua Jiheng Chemical Co., Ltd (China)

Shijiazhuang Donghua Jinlong Chemical Co., Ltd. (China)

Tianjin KingYork Group Co., Ltd. (China)

Yuanshi Hongsheng Chemicals Co. Limited (China)

Exclusive 25 % flat discount (Offer valid till 31st March 2017) @ https://www.wiseguyreports.com/enquiry/905742-glycine-market-research-report

Why buy this Report

This report may help Strategists, Investors, Laboratories, Contract Research Organizations, Biotechnology & Healthcare Companies, Academic Professionals, Drug Approval Authorities, and Other Organizations to –

Identify Market Opportunities
Review and Analyze Global and Regional Markets
Gauge Market Potential for your Products
Identify Competition
Use Market Research for exploring new areas
Acquire Meaningful Guidelines for Strategic Planning
Gear up for Market Entry
Get Actionable Information
Analytics and data presented in each report pertain to several parameters such as –

Global and Regional Market Sizes, Market Shares, Market Trends
Product (Global and Regional) Market Sizes, Market Shares, Market Trends
Technology Trends
Corporate Intelligence
Key Companies By Sales, Brands, Products
Other Strategic Business Affecting Data

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=905742

Continued…

Contact Info:
Name: NORAH TRENT
Email: Sales@Wiseguyreports.Com
Organization: WISE GUY RESEARCH CONSULTANTS PVT LTD
Address: Pune 411028 , Maharashtra, India
Phone: +1-646-845-9349 / +44 208 133 9349

Source URL: http://marketersmedia.com/glycine-value-and-volume-market-2017-market-analytics-by-type-and-application-forecasts-to-2022/165460

For more information, please visit https://www.wiseguyreports.com/sample-request/905742-glycine-market-research-report

Source: MarketersMedia

Release ID: 165460

Arginine Industry Sales, Supply and Consumption 2017 Analysis and Forecasts to 2021

Arginine -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021

Pune, India – January 30, 2017 /MarketersMedia/ —

Arginine Industry

Description

Wiseguyreports.Com Adds “Arginine -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database

This market research report on Arginine, emphasizes on both, its type and application areas. The major types analyzed include for L-Arginine, L-Arginine Monohydrochloride, D-Arginine and Other Arginine; and the major application areas encompass Nutraceuticals, Pharmaceuticals, Personal Care and Other applications (Pet Foods, Fertilizers & Chemical Reagents). The markets are analyzed both in Value (US$) and Volume (Metric Tons).

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/905738-arginine-market-research-report

The report provides essential information including market data, segmentation, market size, key trends, M&A, product developments, industry forecasts, corporate intelligence, and other relevant information. The report lists more than 500 companies that are engaged in Arginine production/manufacture and processing of raw material or end use products . Historic, current and forecast markets are graphically represented by region, by type and by application segment. Compilation of Worldwide Patents and Research related to amino acids and arginine are also presented. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific and Rest of World.

Highlights

Global Arginine market is projected to grow at 3% annually through 2010 – 2022. Today amino acids can be taken as a supplement that is available commercially. Amino acid supplements are usually made from animal protein, vegetable protein, or yeast. While almost all amino acids can be produced in two forms, L and D form. There has been a substantial increase in the demand for amino acids in the last thirty years or so. There is a steady 5-10% growth rate in the market.

It is estimated that in that last ten years the market demand for amino acids has doubled. The increase in the efficiency of the fermentation technology can lead to the development of cheaper goods and thereby increase the overall demand. Subsequently, there is bound to be large-scale production of these products which will lower the costs even more.

Exclusive 25 % flat discount (Offer valid till 31st March 2017) @ https://www.wiseguyreports.com/check-discount/905738-arginine-market-research-report

Key Players

Ajinomoto Co., Inc. (Japan)

Evonik Industries (Germany)

Hubei Qianjiang Siwei Amino Acid Co., Ltd. (China)

Jiahe Biological Technology Co., Ltd. (China)

Kyowa Hakko Europe GmbH (Germany)

Meihua Holdings Group Co.,Ltd. (China)

Shijiazhuang Jirong Pharmaceutical Co., Ltd. (China)

Shine Star (Hubei) Biological Engineering Co. Ltd. (China)

Tianjin Tianan Pharmaceuticals Co.,Ltd. (Chinese)

Wuxi Jinghai Amino Acid Co.,Ltd. (China)

Zhangjiagang Xingyu Technology Co., Ltd. (China)

A & Z Food Additives Co., Ltd. (China)

Aminolabs (Germany)

Atlantic Chemicals Trading GmbH (Germany)

CellMark AB (Sweden)

Direct Food Ingredients Ltd. (UK)

Glanbia Nutritionals (USA)

Green Wave Ingredient (USA)

Prinova Group LLC (USA)

More……..

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=905738

Why buy this Report

Contact Info:
Name: NORAH TRENT
Email: Sales@Wiseguyreports.Com
Organization: WISE GUY RESEARCH CONSULTANTS PVT LTD
Address: Pune 411028 , Maharashtra, India
Phone: +1-646-845-9349 / +44 208 133 9349

Source URL: http://marketersmedia.com/arginine-industry-sales-supply-and-consumption-2017-analysis-and-forecasts-to-2021/165385

For more information, please visit https://www.wiseguyreports.com/sample-request/905738-arginine-market-research-report

Source: MarketersMedia

Release ID: 165385

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ophthotech Corporation, and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / January 30, 2107 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Ophthotech Corporation (“Ophthotech” or the “Company”) (NASDAQ: OPHT). Investors, who purchased or otherwise acquired Ophthotech shares between May 11, 2015 and December 12, 2016 inclusive (the “Class Period”), are encouraged to contact the firm prior to March 13, 2017, also known as the lead plaintiff motion deadline.

If you purchased shares of Ophthotech during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The Complaint states that Ophthotech issued deceptively positive reports about the success and potential of its treatment Fovista, used in combination with Lucentis, an anti-vascular endothelial growth factor agent on the market, despite knowing that the phase 3 clinical trial of Fovista would be unsuccessful in achieving its primary endpoint. According to the Complaint, these statements caused Ophthotech stock to trade at falsely inflated prices.

On December 12, 2016, Ophthotech announced that the trial did not achieve its primary endpoint.

When this information was disclosed to the investing public, the value of Ophthotech stock fell, causing shareholders harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 453883

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Gigamon Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / January 30, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Gigamon Inc., (“Gigamon” or the “Company”) (NYSE: GIMO). Investors, who purchased or otherwise acquired Gigamon shares between October 27, 2016 and January 17, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 28, 2017 lead plaintiff deadline.

If you purchased shares of Gigamon Inc. during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The investigation is centered on whether Gigamon and some of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Gigamon is involved with products and services that provide customers visibility and power over network traffic for corporations and service providers in the United States, as well as various international locations.

On January 18, 2017, Gigamon revealed early fourth quarter and fiscal year 2016 results. In the report, Gigamon stated that fourth quarter revenue for the period ending December 31, 2016 would be significantly less contrasted to the guidance last year. The Company attributed fourth quarter revenue was poor due to “lower than expected product booking” as well as the decision of existing customers to hold “purchasing decisions into 2017.” When this information was disclosed to the public, the value of Gigamon stock fell sharply, causing investors harm.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 453880

IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against OneMain Holdings Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / January 30, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against OneMain Holdings Inc. (“OneMain” or the “Company”) (NYSE: OMF). Investors, who purchased or otherwise acquired OneMain shares between March 3, 2015, and November 7, 2016, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.

If you purchased shares of OneMain during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

OneMain designs, markets, and sells financial products through its subsidiaries. On November 7, 2016, OneMain revealed unsatisfactory third quarter financial results. When this information was revealed to the investing public, the value of OneMain declined, causing investors harm.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 453882

Global K-12 Instruction Materials Market Size, Development Status, Application, Analysis and Forecast 2022

WiseGuyReports.com adds “K-12 Instruction Materials Market 2017 Global Analysis,Growth,Trends and Opportunities Research Report Forecasting to 2022”reports to its database.

Pune, India – January 30, 2017 /MarketersMedia/ —

K-12 Instruction Materials:

Executive Summary

This report studies the global K-12 Instruction Materials market, analyzes and researches the K-12 Instruction Materials development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
Adobe Systems
BlackBoard
Coursera
Educomp Solutions
GP Strategies
Pearson
Sonic Foundry

Market segment by Regions/Countries, this report covers
United States
EU
Japan
China
India
Southeast Asia

Market segment by Application, K-12 Instruction Materials can be split into
Application 1
Application 2

Request Sample Report @ https://www.wiseguyreports.com/sample-request/910372-global-k-12-instruction-materials-market-size-status-and-forecast-2022

Table of Contents

Global K-12 Instruction Materials Market Size, Status and Forecast 2022
1 Industry Overview of K-12 Instruction Materials
1.1 K-12 Instruction Materials Market Overview
1.1.1 K-12 Instruction Materials Product Scope
1.1.2 Market Status and Outlook
1.2 Global K-12 Instruction Materials Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 K-12 Instruction Materials Market by End Users/Application
1.3.1 Application 1
1.3.2 Application 2

2 Global K-12 Instruction Materials Competition Analysis by Players
2.1 K-12 Instruction Materials Market Size (Value) by Players (2015-2016)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future
…..

3 Company (Top Players) Profiles
3.1 Adobe Systems
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 K-12 Instruction Materials Revenue (Value) (2012-2017)
3.1.5 Recent Developments
3.2 BlackBoard
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 K-12 Instruction Materials Revenue (Value) (2012-2017)
3.2.5 Recent Developments
3.3 Coursera
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 K-12 Instruction Materials Revenue (Value) (2012-2017)
3.3.5 Recent Developments
3.4 Educomp Solutions
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 K-12 Instruction Materials Revenue (Value) (2012-2017)
3.4.5 Recent Developments
3.5 GP Strategies
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 K-12 Instruction Materials Revenue (Value) (2012-2017)
3.5.5 Recent Developments
3.6 Pearson
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 K-12 Instruction Materials Revenue (Value) (2012-2017)
3.6.5 Recent Developments
3.7 Sonic Foundry
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 K-12 Instruction Materials Revenue (Value) (2012-2017)
3.7.5 Recent Developments

…CONTINUED

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=910372

Contact Info:
Name: NORAH TRENT
Email: sales@wiseguyreports.com
Organization: WISE GUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers, Magarpatta Road, Hadapsar, Pune – 411028
Phone: +91 841 198 5042

Source URL: http://marketersmedia.com/global-k-12-instruction-materials-market-size-development-status-application-analysis-and-forecast-2022/165457

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 165457

Robotic Exoskeletons 2017 Global Market Expected to Grow at CAGR 40% and Forecast to 2023

WiseGuyReports.Com Publish a New Market Research Report On – “Robotic Exoskeletons 2017 Global Market Expected to Grow at CAGR 40% and Forecast to 2023”.

Pune, India – January 30, 2017 /MarketersMedia/ —

During the forecast 2017-2023 period, global demand for robotic exoskeletons is poised to a cumulative market value of over $3.7 billion including sales, rent, lease, commission fee and other sources. This represents an exceptional and accelerating growth with a CAGR of more than 40% in terms of annual revenue across the globe.

Global Robotic Exoskeletons Market 2016-2023 by Industrial Vertical, Mobility Type, Product Function, Power Technology and Region is based on a comprehensive research of the robotic exoskeletons market by analyzing the entire global market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.

In-depth qualitative analyses include identification and investigation of market structure, growth drivers, restraints and challenges, emerging product trends & market opportunities, Porter’s Fiver Forces, partnership and fundraising landscape. Moreover, risks associated with investing in global robotic exoskeletons market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
The report quantifies global robotic exoskeletons market in every aspect of the classification from perspectives of Industrial Vertical, Mobility Type, Product Function, Power Technology and Region.

Download Sample Report @ https://www.wiseguyreports.com/sample-request/910123-global-robotic-exoskeletons-market-technology-and-region

For more information or any query mail at sales@wiseguyreports.com

Based on industrial vertical, the global market is segmented into the following sections with annual revenue data available for each section over 2014-2023:
• Healthcare Sector (further segmented into Rehabilitation and Mobility Aid by application)
• Military Sector
• Industrial Sector (further segmented into Manufacture, Construction, Logistics, and Other Applications)
• Civilian Sector

On basis of mobility type, the global market is studied in the following segments with annual revenue data provided for each sub-segment covering 2014-2023 duration:
• Mobile Exoskeletons
• Stationary Exoskeletons
• Tethered Exoskeletons

On basis of product function, the global market is studied in the following segments with annual revenue available for each sub-segment covering 2014-2023 duration:
• Upper Body Exoskeletons
• Lower Body Exoskeletons
• Full Body Exoskeletons

On basis of power technology, the global market is segmented into the following sections with annual revenue forecast for each section covering 2014-2023:
• Active Exoskeletons (by power type, this section is further classified into Electric Actuator, Pneumatic Actuator, Hydraulic Actuator, Fuel Cell, and Others)
• Passive Exoskeletons

Geographically, the following five regions together with the listed national markets are fully investigated:
• APAC (China, Japan, South Korea, Australia, India, and Rest of APAC)
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
• North America (U.S. and Canada)
• Latin America
• RoW

For each of the aforementioned regions and countries, detailed analysis and data about annual revenue of robotic exoskeletons are available for every single year over 2014-2023.

The report also includes global annual shipment 2014-2023 based on direct sales, the split of overall revenue by revenue mode over the forecast years, average selling price of robotic exoskeletons for 2014-2023, current competitive scenario and the predicted manufacture trend, and profiles 16 robotic exoskeleton vendors including market leaders and important emerging players.

Highlighted with 22 tables and 83 figures, this 167-page report provides timely data and detailed analysis to help clients targeting the global market to identify business opportunities and benchmark effective strategies.
(Note: The report can be customized/updated per request to meet clients’ needs.)

Complete Report Details @ https://www.wiseguyreports.com/reports/910123-global-robotic-exoskeletons-market-technology-and-region

Table Of Contents – Major Key Points

1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary

2 Market Overview and Qualitative Analysis
2.1 Market Structure
2.2 Market Size and Forecast
2.3 Major Growth Drivers
2.4 Market Restraints and Challenges
2.5 Emerging Opportunities and Market Trends
2.6 Porter’s Fiver Forces Analysis
2.7 Investing in Global Market: Risk Assessment and Management
2.7.1 Risk Evaluation of Global Market
2.7.2 Critical Success Factors (CSFs)

3 Segmentation of Global Market by Industrial Vertical
3.1 Market Overview by Industrial Vertical
3.2 Global Robotic Exoskeletons Market in Healthcare Sector 2014-2023
3.2.1 Global Rehabilitation Exoskeletons Market 2014-2023
3.2.2 Global Mobility Aid Exoskeletons Market 2014-2023
3.3 Global Robotic Exoskeletons Market in Military Sector 2014-2023
3.4 Global Robotic Exoskeletons Market in Industrial Sector 2014-2023
3.4.1 Global Robotic Exoskeletons Market for Industrial Manufacture 2014-2023
3.4.2 Global Robotic Exoskeletons Market for Construction Industry 2014-2023
3.4.3 Global Robotic Exoskeletons Market for Logistics Industry 2014-2023
3.4.4 Global Robotic Exoskeletons Market for Other Industrial Applications 2014-2023
3.5 Global Robotic Exoskeletons Market in Civilian Sector 2014-2023

4 Segmentation of Global Market by Mobility Type
4.1 Market Overview by Mobility Type
4.2 Global Mobile Exoskeletons Market 2014-2023
4.3 Global Stationary Exoskeletons Market 2014-2023
4.4 Global Tethered Exoskeletons Market 2014-2023

5 Segmentation of Global Market by Product Function
5.1 Market Overview by Product Function
5.2 Global Upper Body Exoskeletons Market 2014-2023
5.3 Global Lower Body Exoskeletons Market 2014-2023
5.4 Global Full Body Exoskeletons Market 2014-2023

6 Segmentation of Global Market by Power Technology
6.1 Market Overview by Power Technology
6.2 Global Active Exoskeletons Market 2014-2023
6.2.1 Global Market of Active Exoskeletons with Electric Actuators 2014-2023
6.2.2 Global Market of Active Exoskeletons with Pneumatic Actuators 2014-2023
6.2.3 Global Market of Active Exoskeletons with Hydraulic Actuators 2014-2023
6.2.4 Global Market of Active Exoskeletons with Fuel Cells 2014-2023
6.2.5 Global Market of Active Exoskeletons with Other Power Technology 2014-2023
6.3 Global Passive Exoskeletons Market 2014-2023

7 Segmentation of Global Market by Region
7.1 Geographic Market Overview by Region 2016-2023
7.2 North America Market 2014-2023
7.2.1 Overview of North America Market
7.2.2 U.S. Market
7.2.3 Canadian Market
7.3 European Market 2014-2023
7.3.1 Overview of European Market
7.3.2 Germany
7.3.3 France
7.3.4 UK
7.3.5 Italy
7.3.6 Spain
7.3.7 Rest of European Market
7.4 Asia-Pacific Market 2014-2023
7.4.1 Overview of Asia-Pacific Market
7.4.2 Japan
7.4.3 China
7.4.4 South Korea
7.4.5 Australia
7.4.6 India
7.4.7 Rest of APAC Region
7.5 Latin America Market 2014-2023
7.6 Rest of World Market 2014-2023

8 Competitive Landscape
8.1 Overview of Global Vendors
8.2 Key M&A Trends and Strategic Partnerships
8.3 Fundraising in Global Market
8.4 Recent Product Launches and Development
8.5 Company Profiles (16 Vendors)

………..CONTINUED

For more information or any query mail at sales@wiseguyreports.com

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=910123

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of rmaket research reports under these categories and sub-categories.

Contact Info:
Name: Norah Trent
Email: sales@wiseguyreports.com
Organization: WiseGuy Research Consultants Pvt Ltd.
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune – 411028
Phone: +1-646-845-9349

Source URL: http://marketersmedia.com/robotic-exoskeletons-2017-global-market-expected-to-grow-at-cagr-40-and-forecast-to-2023/165383

For more information, please visit https://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 165383

IMPORTANT CLASS PERIOD UPDATE FOR BANC INVESTORS: Khang & Khang LLP Announces Securities Class Action Lawsuit against Banc of California, Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / January 30, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Banc
of California, Inc. (“Banc” or the “Company”) (NYSE: BANC). Investors, who purchased or otherwise acquired Banc shares between August 7, 2015 and January 23, 2017 inclusive (the “Class Period”), should contact the firm prior to the March 24, 2017 lead plaintiff motion deadline.

If you purchased shares of Banc during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

Seeking Alpha released an article alleging that Banc of California had hidden numerous connections between it and Jason Galanis, who has been convicted of criminal securities fraud. In particular, the Complaint alleges that: Banc of California CEO Jason Sugarman was the founder, CEO, and indirect owner of a company controlled by Galanis; and that separately, Galanis controlled Banc of California’s establishing shareholder. The Complaint further alleges that Banc of California was utilizing an off-balance sheet entity to provide loans to insiders.

Then, on November 10, 2016, Banc of California revealed it would be stalling the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 so that its Special Committee could complete a review into the aforementioned improper relationships and related party transactions.

On January 23, 2017, Banc of California revealed that the Securities and Exchange Commission is pursuing a formal order of investigation directed at these same issues. When this information was disclosed to the public, the value of Banc fell, causing investors serious harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 453878